August 6, 2026
Upcoming Drug-Resistant Tuberculosis Webinars: August 19 & August 20, 9:00 AM EST
On Aug. 19 & 20, TAG is hosting a two-part webinar covering WHO guideline updates for pre-extensively drug-resistant TB and approaches to addressing additional bedaquiline-resistance (extensively drug-resistant TB).
July 20, 2026
Letters Advocating for the Adoption of Near-Point-of-Care TB tests
Letter / Comment
TAG and the Global TB CAB have a long history of advocating for the uptake of new health innovations, influencing global and national decision-making, and supporting policy translation. In March 2026, the World Health Organization (WHO) recommended a new class of tests — near point-of-care (NPOC) molecular tests — that…
July 13, 2026
Why So Long? A Call for a More Humane Tuberculosis Treatment and Meaningful Community Engagement
Poetry can be used as a form of public health. In a recently written poem, LAT CAB member Bakyt Myrzaliev speaks about the trials and tribulations of tuberculosis treatment – writing passionately and inquisitively about side effects, the high burden of countless pills, and ultimately calling for investments into newer…
July 9, 2026
Webinar: Implementing the 4-month HPMZ Regimen: Experience, Tools, and Next Steps
Webinar / Presentation
The WHO Global TB Program’s Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization’s (WHO) 2022 recommendation, implementation has remained limited,…
July 6, 2026
Community Research Advisors Group (CRAG) Consultant
Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.
June 23, 2026
Overcoming Barriers to Adopting the Four-Month Regimen: A Pathfinding Mission to Improve Access to Newer TB Treatments
Publication
A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access
June 16, 2026
Community and Civil Society Engagement Case Studies
The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.
May 26, 2026
Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care
Webinar / Presentation
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by…
May 15, 2026
But…I’m a TB Activist? Perspectives from a Health Advocate on the Ground from the World Bank & International Monetary Fund Spring Meetings
The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid has not generated sustainable, country-led financing for health. Now, governments are scrambling to fill funding gaps to provide life-saving care.
May 15, 2026
Financing Health Equity
The Promise and Potential of Economic Reforms for Health The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid from bilateral and multilateral donors has not generated sustainable, country-led financing for health. Now, governments are…
May 5, 2026
Where Science Meets Justice: Before Most of Us Wake Up, TAG is Already Defending HIV Progress
Treatment Action Group’s (TAG) HIV team works across the country to achieve a shared mission: end the HIV epidemic through science, policy, and advocacy. As a remote team, the reach is national but the urgency is personal. At a time when progress is possible and precarious, the team ensures that…
April 23, 2026
The Path Forward: TAG’s Vision for HIV, TB, and Hepatitis C
TAG’s leadership and staff broke down the latest in HIV, TB, and hepatitis C research and advocacy. See where the work stands and where it’s headed.
April 15, 2026
TAG Statement on Results of the PreVenTB Phase III Trial of TB Vaccine Candidates VPM1002 and Immuvac
Statement / Press
Well-conducted study sponsored by Indian Council of Medical Research did not meet primary efficacy endpoint of preventing microbiologically confirmed TB disease
April 8, 2026
The CDC’s Unjustified Halt on Testing for Dangerous Pathogens is Bad for Everyone’s Health – TAG Calls for CDC to Immediately Reinstate Essential Diagnostic Testing
Statement / Press
CDC pauses rabies, mpox, and other infectious disease testing amid budget cuts and staffing losses, raising urgent public health concerns.
April 7, 2026
TAG Public Comments for the AIDS Research Advisory Council (ARAC) Meeting, April 6, 2026: Renewing Funding for the HIV Clinical Trial Networks
Letter / Comment
TAG recommends that the AIDS Research Advisory Council (ARAC) endorse NIAID’s continued support of a balanced and comprehensive portfolio of basic, clinical, and implementation science — including a funding opportunity to renew its four current networks: the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG), the International Maternal…
